Javascript must be enabled to continue!
IDENTIFICATION OF NEW CYCLOOXYGENASE-2 SELECTIVE INHIBITORS VIA VIRTUAL SCREENING AND COMPLEX-BASED PHARMACOPHORE MAPPING
View through CrossRef
Background: New and effective COX-2-targeted medications may cure cancer, inflammation, and other disorders.It’s difficult to produce druggable site inhibitors for target protein inhibition that are strong and selective. Such medications need a more informed structure-based or ligand-based drug discovery technique. MOE was used to create asix-point COX-2 selective inhibitor pharmacophore from 43 compounds. The structure includes three aromatic rings,one hydrophobic group (Hyd), one donor (Don), and three H-bond acceptors. A pharmacophore was used to digitallyfilter the Chembridge database to locate additional structural poses that fulfilled the model’s requirements. We found2090 structurally diverse hits after filtering. Molecular docking was performed on 767 hits after Lipinski’s rule of fivedetermined druggability. Twenty compounds with high active site amino acid residue interactions and diverse scaffoldswere chosen. The first COX-2 isoform-inhibiting medicines were discovered using structure-based pharmacophores.Objectives Using complex-based pharmacophore mapping and virtual screening, this research seeks novel selectiveCOX-2 inhibitors. This involves filtering through a chemical database, defining critical interactions, maximizing hits,and extending drug development for safer and more effective inflammation and pain managemStudy design : Employing Advanced Computational And Pharmacological Approaches StudyDuration and place of study :The study was conducted at Abdul Wali Khan University Mardan from jan2017 to jan 2018Methods: The investigation used a structure-based drug discovery methodology to find novel cyclooxygenase-2 (COX-2)selective inhibitors. The COX-2 crystal structure was used to create a pharmacophore model, which was then used tovirtually search a chemical database. In order to identify potential lead compounds based on interactions with importantCOX-2 residues, binding energies were computed, and molecular docking was used to refine hits.Results: The goal of the project was to use virtual screening and complex-based pharmacophore mapping to findnovel selective COX-2 inhibitors. After the COX-2 crystal structure was used to create a pharmacophore model,2090 hits were discovered in a database. Following the druggability assessment, 767 hits were chosen for moleculardocking. Ultimately, twenty compounds were found to be promising COX-2 inhibitors due to their strong interactionswith COX-2 and variety of scaffolds.Conclusion: This study found 20 possible lead drugs that selectively block cyclooxygenase-2 (COX-2) using complex-based pharmacophore mapping and virtual screening. These substances show a variety of scaffolds and robustinteractions with COX-2, making them attractive candidates for further research and development as anti-inflammatoryand anti-cancer medications with maybe fewer adverse effects.Keywords: Cyclooxygenase-2 (COX-2),Pharmacophore mapping,Virtual screening,Drug discovery
Bacha Khan Medical College
Title: IDENTIFICATION OF NEW CYCLOOXYGENASE-2 SELECTIVE INHIBITORS VIA VIRTUAL SCREENING AND COMPLEX-BASED PHARMACOPHORE MAPPING
Description:
Background: New and effective COX-2-targeted medications may cure cancer, inflammation, and other disorders.
It’s difficult to produce druggable site inhibitors for target protein inhibition that are strong and selective.
Such medications need a more informed structure-based or ligand-based drug discovery technique.
MOE was used to create asix-point COX-2 selective inhibitor pharmacophore from 43 compounds.
The structure includes three aromatic rings,one hydrophobic group (Hyd), one donor (Don), and three H-bond acceptors.
A pharmacophore was used to digitallyfilter the Chembridge database to locate additional structural poses that fulfilled the model’s requirements.
We found2090 structurally diverse hits after filtering.
Molecular docking was performed on 767 hits after Lipinski’s rule of fivedetermined druggability.
Twenty compounds with high active site amino acid residue interactions and diverse scaffoldswere chosen.
The first COX-2 isoform-inhibiting medicines were discovered using structure-based pharmacophores.
Objectives Using complex-based pharmacophore mapping and virtual screening, this research seeks novel selectiveCOX-2 inhibitors.
This involves filtering through a chemical database, defining critical interactions, maximizing hits,and extending drug development for safer and more effective inflammation and pain managemStudy design : Employing Advanced Computational And Pharmacological Approaches StudyDuration and place of study :The study was conducted at Abdul Wali Khan University Mardan from jan2017 to jan 2018Methods: The investigation used a structure-based drug discovery methodology to find novel cyclooxygenase-2 (COX-2)selective inhibitors.
The COX-2 crystal structure was used to create a pharmacophore model, which was then used tovirtually search a chemical database.
In order to identify potential lead compounds based on interactions with importantCOX-2 residues, binding energies were computed, and molecular docking was used to refine hits.
Results: The goal of the project was to use virtual screening and complex-based pharmacophore mapping to findnovel selective COX-2 inhibitors.
After the COX-2 crystal structure was used to create a pharmacophore model,2090 hits were discovered in a database.
Following the druggability assessment, 767 hits were chosen for moleculardocking.
Ultimately, twenty compounds were found to be promising COX-2 inhibitors due to their strong interactionswith COX-2 and variety of scaffolds.
Conclusion: This study found 20 possible lead drugs that selectively block cyclooxygenase-2 (COX-2) using complex-based pharmacophore mapping and virtual screening.
These substances show a variety of scaffolds and robustinteractions with COX-2, making them attractive candidates for further research and development as anti-inflammatoryand anti-cancer medications with maybe fewer adverse effects.
Keywords: Cyclooxygenase-2 (COX-2),Pharmacophore mapping,Virtual screening,Drug discovery.
Related Results
Role of COX-2 in the Enhanced Vasoconstrictor Effect of Arachidonic Acid in the Diabetic Rat Kidney
Role of COX-2 in the Enhanced Vasoconstrictor Effect of Arachidonic Acid in the Diabetic Rat Kidney
In the rat isolated perfused kidney, arachidonic acid elicits cyclooxygenase-dependent vasoconstriction through activation of PGH
2
/TxA
2
...
Therapeutic potential of SGLT-2 inhibitors and DDP4 inhibitors in elderly patients with type 2 diabetes mellitus and benign prostatic hyperplasia
Therapeutic potential of SGLT-2 inhibitors and DDP4 inhibitors in elderly patients with type 2 diabetes mellitus and benign prostatic hyperplasia
Background. Benign prostatic hyperplasia (BPH) has recently been linked to diabetes mellitus and insulin resistance. This study aims to explore whether the use of either sodium-glu...
Pharmacophore model guided 3D molecular generation through diffusion model
Pharmacophore model guided 3D molecular generation through diffusion model
Generating molecules that rigorously satisfy three-dimensional (3D) pharmacophore constraints has remained a challenge in de novo drug design, despite rapid progress in molecular g...
Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis
Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis
IntroductionThis meta-analysis aims to evaluate the efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors [PD-(L)1 inhibitors] for muscle-invasive bladder carcinom...
PP-MAPS: dynamic pharmacophore signatures of protein–peptide interfaces from molecular dynamics trajectories
PP-MAPS: dynamic pharmacophore signatures of protein–peptide interfaces from molecular dynamics trajectories
Abstract
Protein–peptide interactions underlie many cellular signaling and regulatory processes and are increasingly exploited in drug discovery. Characterizing suc...
Mapping workflow trends in pulsed-field ablation procedures: an international glimpse
Mapping workflow trends in pulsed-field ablation procedures: an international glimpse
Abstract
Background
As pulsed field ablation (PFA) is increasingly used in the EP lab, the use of mapping, fluoroscopy, and intr...
EFEKTIFITAS PELATIHAN LABORATORIUM VIRTUAL SEBAGAI MEDIA PEMBELAJARAN BAGI GURU KIMIA
EFEKTIFITAS PELATIHAN LABORATORIUM VIRTUAL SEBAGAI MEDIA PEMBELAJARAN BAGI GURU KIMIA
EFFECTIVITY OF VIRTUAL LABORATORY TRAINING AS A LEARNING MEDIA FOR CHEMISTRY TEACHERSAchmad Lutfi, SukarminUniversitas Negeri Surabaya, Indonesia achmadlutfi@unesa.ac.idAbstractThe...
Anti-Tumor Activity of Immunoproteasome Selective Inhibitors.
Anti-Tumor Activity of Immunoproteasome Selective Inhibitors.
Abstract
Background: The immunoproteasome is a form of the proteasome that is distinct from the broadly expressed constitutive proteasome. The immunoproteasome, whic...

